Alpha PRRT with RYZ401 in PRRT-naive Solid Tumors Expressing SSTRs

Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs

IDENTIFIER (ClinicalTrials.gov): NCT07165132

DRUG/TREATMENT: RYZ401

PHASE: 1

STATUS: Recruiting soon

SPONSOR: Rayzebio

DESCRIPTION:

This clinical trial is testing a new treatment called RYZ401 in people with certain neuroendocrine tumors (NETs) and other solid tumors that have a protein on their cells called SSTR (somatostatin receptor). RYZ401 is an investigational (not yet approved) drug — meaning this study is meant to learn how safe it is and whether it may help treat these cancers.

Who Can Join

Adults aged 18 or older with a confirmed NET or other SSTR-positive cancer (such as certain neuroendocrine tumors or related solid tumors) may be eligible.

What Will Happen During the Study

• The study includes a dose-finding (dose escalation) phase and a dose-expansion phase.

• Participants will receive RYZ401 and be monitored carefully for safety, side effects, and how their body handles the drug.

• Researchers will also look for early signs of benefit — for example, whether the tumor shrinks or stops growing.

Why This Study Matters

If RYZ401 proves to be safe and effective, it could become a new treatment option for patients with neuroendocrine tumors or other SSTR-positive cancers — especially those who may not have many other treatment choices.

For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to  view this trial here.

CONTACT

Name: RayzeBio Clinical Trials

Phone Number: +1 619-657-0057

Email: clinicaltrials@rayzebio.com

This is a multicenter trial with various locations. Go to the “Contacts and Locations” section of this trial page at ClinicalTrials.gov for site-specific contact information.